United Therapeutics (UTHR) director logs small 50-share sale in Form 4

Q: What insider transaction did UTHR director Malcolm Jan report?

Malcolm Jan, a director of United Therapeutics (UTHR) , reported selling 50 shares of the company’s common stock on January 16, 2026 .

Q: At what price were the United Therapeutics (UTHR) shares sold in this Form 4?

The reported transaction shows a sale price of $460.98 per share for the 50 shares of United Therapeutics common stock.

Q: Was the UTHR insider sale made under a Rule 10b5-1 plan?

Yes. The filing states that the sale was made pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 11, 2025 .

Q: What role does the reporting person hold at United Therapeutics (UTHR)?

The reporting person, Malcolm Jan , is identified in the filing as a director of United Therapeutics Corporation.

Q: Is this UTHR Form 4 filed for an individual or a group?

The document indicates that the Form 4 was filed by one reporting person , not by a group.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

United Therapeutics director Malcolm Jan reported a small planned stock sale. On January 16, 2026, he sold 50 shares of United Therapeutics common stock at $460.98 per share in an open market transaction coded as a sale. The filing notes that this trade was executed under a pre-established Rule 10b5-1 trading plan that the reporting person entered into on September 11, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this transaction, he beneficially owned 320 shares of the company’s common stock in direct ownership.

Insider Trade Summary

Net Seller: 50 shares ($23,049)

Net Sell 1 txn

Insider MALCOLM JAN

Role Director

Sold 50 shs ($23K)

Type	Security	Shares	Price	Value
Sale	Common Stock	50	$460.98	$23K

Holdings After Transaction: Common Stock — 320 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/20/2026 - 04:30 PM

FAQ

What insider transaction did UTHR director Malcolm Jan report?

Malcolm Jan, a director of United Therapeutics (UTHR), reported selling 50 shares of the company’s common stock on January 16, 2026.

At what price were the United Therapeutics (UTHR) shares sold in this Form 4?

The reported transaction shows a sale price of $460.98 per share for the 50 shares of United Therapeutics common stock.

How many United Therapeutics (UTHR) shares does Malcolm Jan hold after this transaction?

Following the reported sale, Malcolm Jan beneficially owned 320 shares of United Therapeutics common stock in direct ownership.

Was the UTHR insider sale made under a Rule 10b5-1 plan?

Yes. The filing states that the sale was made pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 11, 2025.

What role does the reporting person hold at United Therapeutics (UTHR)?

The reporting person, Malcolm Jan, is identified in the filing as a director of United Therapeutics Corporation.

Is this UTHR Form 4 filed for an individual or a group?

The document indicates that the Form 4 was filed by one reporting person, not by a group.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MALCOLM JAN

(Last)

(First)

(Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING

20910

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/16/2026		S⁽¹⁾		50	D	$460.98	320	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 11, 2025.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR